| Halaven (eribulin mesylate) / Eisai |
NCT01142661: Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies |
|
|
| Completed | N/A | 9 | US | Eribulin Mesylate | Eisai Inc. | Breast Cancer | 08/11 | | | |
| Completed | N/A | 112 | Europe | | Eisai Farmacêutica S.A. | Metastatic Breast Cancer | 10/12 | 11/12 | | |
NCT01463891: Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) |
|
|
| Completed | N/A | 963 | Japan | Eribulin Mesylate | Eisai Co., Ltd. | Inoperable or Recurrent Breast Cancer | 12/12 | 11/13 | | |
| Completed | N/A | 45 | Europe | | Eisai Limited | Breast Cancer | 06/14 | 06/14 | | |
NCT01240421 / 2009-017671-22: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory |
|
|
| Approved for marketing | N/A | | Canada, Europe | Eribulin Mesylate | Eisai Inc. | Metastatic Breast Cancer | 03/15 | 11/14 | | |
NCT02443428: Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry |
|
|
| Completed | N/A | 77 | Europe | | Eisai Limited | Breast Cancer | 10/15 | 10/15 | | |
NCT02863146: Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer |
|
|
| Terminated | N/A | 23 | Europe | | Centre Oscar Lambret, Eisai Inc. | Breast Cancer, Metastatic Breast Cancer | 07/17 | 09/17 | | |
NCT02371174: Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. |
|
|
| Completed | N/A | 651 | Japan | | Eisai Co., Ltd. | Breast Cancer, HER2-negative Breast Cancer | 01/18 | 01/18 | | |
